Walgreens Boots Alliance (NASDAQ:WBA) had its target price upped by Pivotal Research from $60.00 to $72.00 in a research report sent to investors on Monday morning. The brokerage currently has a hold rating on the pharmacy operator’s stock.
A number of other analysts have also issued reports on the company. Zacks Investment Research upgraded Walgreens Boots Alliance from a hold rating to a buy rating and set a $81.00 price target for the company in a report on Tuesday, September 25th. ValuEngine upgraded Walgreens Boots Alliance from a strong sell rating to a sell rating in a report on Friday, September 21st. Robert W. Baird boosted their price target on Walgreens Boots Alliance from $64.00 to $69.00 and gave the company a neutral rating in a report on Tuesday, September 11th. Cowen lowered Walgreens Boots Alliance from an outperform rating to a market perform rating and set a $104.00 price target for the company. in a report on Monday, July 23rd. Finally, BidaskClub upgraded Walgreens Boots Alliance from a hold rating to a buy rating in a report on Wednesday, September 12th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. Walgreens Boots Alliance presently has an average rating of Hold and a consensus price target of $78.22.
WBA opened at $76.58 on Monday. The company has a market cap of $72.35 billion, a PE ratio of 15.02, a price-to-earnings-growth ratio of 1.11 and a beta of 1.04. Walgreens Boots Alliance has a one year low of $59.07 and a one year high of $80.68. The company has a current ratio of 0.93, a quick ratio of 0.47 and a debt-to-equity ratio of 0.44.
Walgreens Boots Alliance (NASDAQ:WBA) last released its earnings results on Thursday, October 11th. The pharmacy operator reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.03. The firm had revenue of $33.44 billion for the quarter, compared to analysts’ expectations of $33.64 billion. Walgreens Boots Alliance had a return on equity of 21.22% and a net margin of 3.36%. As a group, equities research analysts predict that Walgreens Boots Alliance will post 5.98 earnings per share for the current year.
In other Walgreens Boots Alliance news, Director William C. Foote sold 2,736 shares of the company’s stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $65.99, for a total transaction of $180,548.64. Following the completion of the sale, the director now owns 10,943 shares in the company, valued at $722,128.57. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 14.80% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the business. Sei Investments Co. increased its position in shares of Walgreens Boots Alliance by 100.9% during the second quarter. Sei Investments Co. now owns 349,451 shares of the pharmacy operator’s stock worth $20,970,000 after purchasing an additional 175,551 shares in the last quarter. California Public Employees Retirement System increased its position in shares of Walgreens Boots Alliance by 7.7% during the second quarter. California Public Employees Retirement System now owns 2,303,917 shares of the pharmacy operator’s stock worth $138,270,000 after purchasing an additional 165,048 shares in the last quarter. Bridgewater Associates LP increased its position in shares of Walgreens Boots Alliance by 109.1% during the second quarter. Bridgewater Associates LP now owns 657,649 shares of the pharmacy operator’s stock worth $39,469,000 after purchasing an additional 343,062 shares in the last quarter. Schaller Investment Group Inc. acquired a new position in shares of Walgreens Boots Alliance during the second quarter worth $9,152,000. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Walgreens Boots Alliance by 4.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 3,563,249 shares of the pharmacy operator’s stock worth $213,849,000 after purchasing an additional 150,763 shares in the last quarter. Institutional investors own 61.92% of the company’s stock.
About Walgreens Boots Alliance
Walgreens Boots Alliance, Inc operates as a pharmacy-led health and wellbeing company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics.
Further Reading: Bond
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.